PET/CT scan to study why prostate cancer resists treatment
Part of Cancer, Kidney & urinary clinical trials.
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by biopsy (adenocarcinoma).
- Your cancer has spread to at least one place seen on CT scan or a bone scan.
- Your PSA blood test shows progression: at least two rises from its lowest point, and your PSA is at least 2 ng/mL (study has specific “intrinsic” vs “acquired” pathways).
- You must be able to get imaging that takes time while lying flat for at least 30 minutes.
- You must be able to consent for yourself, speak English, and not be incarcerated.
- Your overall health should suggest you can live at least 12 more months, and you must be able to follow study visit instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
This trial studies how a special PET/CT scan (using 18F-DCFPyL) helps evaluate prostate cancer that is either high-risk at diagnosis or has come back based on PSA blood tests. It may help your care team better stage (map) the cancer and guide next steps.
This trial provides access to a new type of PET/CT scan called 18F-PSMA-1007, which uses a radioactive tracer to find prostate cancer cells that may have spread in the body. The scan may help your doctor plan your treatment more accurately.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.